ExploreWatchlistsPricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Operating margin (%)

ReproCELL Incorporated (4978)

Market cap
¥16.4B
P/E ratio
-28.5x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Mar 31, 2025-4.4-74.04%
Mar 31, 2024-16.9+39.82%
Mar 31, 2023-12.1-58.35%
Mar 31, 2022-29-64.46%
Mar 31, 2021-81.5+7.56%
Mar 31, 2020-75.8+5.56%
Mar 31, 2019-71.8-35.20%
Mar 31, 2018-110.7+47.51%
Mar 31, 2017-75.1-21.85%
Mar 31, 2016-96.1-26.46%
Mar 31, 2015-130.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat